Tag: cancer
-
Bionxt Solutions (BNXT.C): Seeking to confirm national-level cancer drug patent
As the world increasingly faces the complexities of autoimmune and neurodegenerative diseases, new medical advancements are crucial to better serve patients’ needs. Enter Bionxt Solutions Inc. (BNXT.C), a bioscience innovator making moves with its groundbreaking sublingual (under-the-tongue) drug delivery technology. This technology, now in the process of securing national-level patents globally, represents a shift from…
-
ERYTECH Pharma (ERYP.Q) has a GRASPA® on ALL, shares up +70%
A Need for Alternatives $54.898M Market Capitalization ERYTECH Pharma (ERYP.Q) announced today that the Company has sold its US manufacturing facility to Catalent, a leading contract development and manufacturing organization (CDMO) in advanced therapies. Under the terms of the agreement, Catalent has agreed to purchase ERYTECH’s US facility for a total consideration of $44.5 million. That’s…
-
Perimeter Medical Imaging AI (PINK.V) Fights Back Against Cancer
An Insatiable Disease Cancer is a grim disease, feeding off numerous sources including tobacco, infections, environmental pollution, occupational carcinogens, and radiation, among others. Whether directly or indirectly, everyone has experienced the effects of cancer at some point in their life. Wincing pain, weight loss, and an overwhelming feeling of fatigue all plagued my mom as…
-
First Glance with Jody Vance – Medexus Pharma (MDP.T)
Vancouver’s own Jody Vance speaks with Ken d’Entremont, Medexus Pharmaceuticals (MDP.V) CEO and director, to find out more about the company’s mandate of bringing established drugs approved in other countries to patients in Canada. Listen in! <div algn=”center:><iframe width=”803″ height=”452″ src=”https://www.youtube.com/embed/r4MwrGgePDo” title=”YouTube video player” frameborder=”0″ allow=”accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture” allowfullscreen></iframe></div>
-
Today’s Idea: Medexus Pharmaceuticals (MDP.T) Continues to Climb the North American Pharmaceuticals Ladder
Cancer is a bitch. Even if you haven’t had to battle against cancer yourself, you likely know someone who has. Unfortunately for me, that person was my mom; however, before this turns into a sob story let me assure you that my mom is alive and well after kicking cancer’s ass. My mom was diagnosed…
-
Perimeter Medical Imaging AI (PINK.V) latest study is the latest assault in the war on cancer
More than terrorism, drugs, racial animus and acts of God, cancer has always been with us. It’s humanity’s number one enemy throughout history—it’s only recently that we’ve learned what little we know, and devised rudimentary strategies on how to secure its defeat. The statistics are harrowing. Do a headcount next time during your commute then…
-
Perimeter Medical Imaging AI (PINK.V) technology advances as ACS reports 2.3 million new breast cancer cases
In 25% of Breast Lumpectomy surgeries, cancerous material is left behind. With current technology, the surgeon needs to wait about a week, to see if he’s got all the cancerous material.
-
Perimeter Medical Imaging AI (PINK.V): the power of a simple story
No need to cut the patient open again later. The surgeon can make adjustments on the fly.
-
Perimeter Medical Imaging AI (PINK.V) shuffles the deck
PINK is accelerating toward the commercialisation of the OTIS platform. It has already received a $7.4 million grant (non-dilutive capital) from the Cancer Prevention and Research Institute of Texas (CPRIT) to fund the ATLAS AI Project.
-
Perimeter Medical Imaging AI (PINK.V) untapped value in medtech
Investing your money in health or medical companies is difficult. The complexity of the science often deters investors from allocating a portion of their portfolio to said industry, despite those companies having proven potential to provide the largest gains for its investors. We’re not criticizing – everyone knows that medical terminology is only second to…